Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Share-based Compensation (2018 - 2025)

Organogenesis Holdings (ORGO) has 8 years of Share-based Compensation data on record, last reported at $4.3 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 49.57% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $13.3 million, up 25.71%, while the annual FY2025 figure was $13.3 million, 25.71% up from the prior year.
  • Share-based Compensation reached $4.3 million in Q4 2025 per ORGO's latest filing, up from $3.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.3 million in Q4 2025 and bottomed at $698000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $2.2 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 233.97% in 2021, then dropped 1.01% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.1 million in 2021, then surged by 71.28% to $1.9 million in 2022, then increased by 27.55% to $2.4 million in 2023, then rose by 22.19% to $2.9 million in 2024, then skyrocketed by 49.57% to $4.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $4.3 million in Q4 2025, $3.1 million in Q3 2025, and $2.5 million in Q2 2025.